Compare GAIN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAIN | ARVN |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.5M | 600.2M |
| IPO Year | 2005 | 2018 |
| Metric | GAIN | ARVN |
|---|---|---|
| Price | $15.87 | $8.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $14.75 | ★ $15.05 |
| AVG Volume (30 Days) | 150.3K | ★ 711.6K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | 20.63 | ★ 58.84 |
| EPS | 0.76 | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | $21.12 | ★ $4.89 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.14 | $6.97 |
| 52 Week High | $17.14 | $14.22 |
| Indicator | GAIN | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 38.71 |
| Support Level | $15.78 | $7.90 |
| Resistance Level | $16.94 | $8.40 |
| Average True Range (ATR) | 0.28 | 0.32 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 17.50 | 11.88 |
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S., to achieve and grow current income by investing in debt securities of established businesses, and to provide stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.